Corten Capital and Ampersand complete Beacon Intelligence deal

Corten Capital and Ampersand Capital Partners have completed a transaction for Beacon Intelligence, a data business covering complex drug modalities, according to PE Hub. Corten acquired Beacon from Hanson Wade Group, an events and conferences operator backed by Graphite Capital, while Ampersand participated as a minority co-investor.

The deal adds a specialist healthcare data asset to Corten’s portfolio and marks the third investment from Corten Capital II, PE Hub reported. That fund closed in March 2024 with €680 million in commitments, according to the same report.

Beacon operates across 16 data modules focused on complex drug modalities, PE Hub reported. The available information did not include financial terms, leverage details, management arrangements or the ownership percentage taken by Ampersand.

Deal structure

In the reported structure, Corten is the acquiring sponsor and Ampersand is taking a minority co-investor role. A minority co-investment typically gives an investor exposure to the asset without control of the company. Control rights, governance terms and economics depend on the transaction documents, none of which were reported by PE Hub.

The seller, Hanson Wade Group, is described by PE Hub as an events and conferences operator. Hanson Wade is backed by Graphite Capital, making the transaction a sale of Beacon out of a Graphite-backed group rather than a primary fundraising round for Beacon, based on the details reported.

For Corten, the transaction follows the closing of Corten Capital II in March 2024. PE Hub reported that the vehicle secured €680 million in commitments and that the Beacon deal is its third investment. No further information was provided on the fund’s prior investments or deployment pace.

Market context

The acquisition sits at the intersection of private equity, healthcare information services and biopharma data. Beacon’s reported coverage of 16 data modules suggests the business serves users seeking structured information across specialised areas of drug development, although PE Hub did not provide customer categories, revenue figures or product-level detail.

Ampersand Capital Partners’ participation as a minority co-investor places a second sponsor alongside Corten in the transaction. PE Hub did not report whether Ampersand invested through a fund, a co-investment vehicle or another structure.

The report also did not disclose advisers, regulatory approvals, closing conditions or timing beyond stating that the acquisition has been completed. The confirmed facts are the buyer group, the seller, Beacon’s data-module footprint, the Graphite backing of Hanson Wade and the fund context for Corten Capital II.

This story draws on original reporting from PE Hub.